|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pectasides D, Kamposioras K, Papaxoinis G
and Pectasides E: Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li SH, Shin DH, Chun YS, Lee MK, Kim MS
and Park JW: A novel mode of action of YC-1 in HIF inhibition:
Stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}.
Mol Cancer Ther. 7:3729–3738. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lou JJ, Chua YL, Chew EH, Gao J, Bushell M
and Hagen T: Inhibition of hypoxia-inducible factor-1alpha
(HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS
One. 5:e105222010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiesener MS, Jurgensen JS, Rosenberger C,
Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei
UA, Pugh CW, et al: Widespread hypoxia-inducible expression of
HIF-2alpha in distinct cell populations of different organs. FASEB
J. 17:271–273. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao ZJ, Yuan WD, Yuan JQ, Yuan K and Wang
Y: Downregulation of HIF-2α reverse the chemotherapy resistance of
lung adenocarcinoma a549 cells to cisplatin. Med Sci Monit.
24:1104–1111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Xue M and Chung DC: c-Myc is
regulated by HIF-2α in chronic hypoxia and influences sensitivity
to 5-FU in colon cancer. Oncotarget. 7:78910–78917. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pereira DM, Rodrigues PM, Borralho PM and
Rodrigues CM: Delivering the promise of miRNA cancer therapeutics.
Drug Discov Today. 18:282–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li S, Yang F, Wang M, Cao W and Yang Z:
miR-378 functions as an onco-miRNA by targeting the
ST7L/Wnt/β-catenin pathway in cervical cancer. Int J Mol Med.
40:1047–1056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang H, Luo R, Chen X, Zhao Y and Tan A:
miR-187 inhibits the growth of cervical cancer cells by targeting
FGF9. Oncol Rep. 38:1977–1984. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li YY, Shao JP, Zhang SP, Xing GQ and Liu
HJ: miR-519d-3p inhibits cell proliferation and invasion of gastric
cancer by downregulating B-cell lymphoma 6. Cytogenet Genome Res.
154:12–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ye X and Lv H: MicroRNA-519d-3p inhibits
cell proliferation and migration by targeting TROAP in colorectal
cancer. Biomed Pharmacother. 105:879–886. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma L and Li J: MicroRNA-519d-3p inhibits
cell proliferation and cell cycle G1/S transition in glioma by
targeting CCND1. Biosci Biotechnol Biochem. 84:297–304. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang L, Shi S, Shi Q, Zhang H, Xia Y and
Zhong T: MicroRNA-519d-3p inhibits proliferation and promotes
apoptosis by targeting HIF-2α in cervical cancer under hypoxic
conditions. Oncol Res. 26:1055–1062. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feng Y, Zou W, Hu C, Li G, Zhou S, He Y,
Ma F, Deng C and Sun L: Modulation of CASC2/miR-21/PTEN pathway
sensitizes cervical cancer to cisplatin. Arch Biochem Biophys.
623-624:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu H, Luo H, Zhang W, Shen Z, Hu X and
Zhu X: Molecular mechanisms of cisplatin resistance in cervical
cancer. Drug Des Devel Ther. 10:1885–1895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Small W Jr, Bacon MA, Bajaj A, Chuang LT,
Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR,
Viswanathan AN and Gaffney DK: Cervical cancer: A global health
crisis. Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Drayton RM: The role of microRNA in the
response to cisplatin treatment. Biochem Soc Trans. 40:821–825.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lei C, Wang Y, Huang Y, Yu H, Huang Y, Wu
L and Huang L: Up-regulated miR155 reverses the
epithelial-mesenchymal transition induced by EGF and increases
chemo-sensitivity to cisplatin in human Caski cervical cancer
cells. PloS One. 7:e523102012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Q, Chang Z, Wang W and Wang B:
Rapamycin-mediated mTOR inhibition reverses drug resistance to
adriamycin in colon cancer cells. Hepatogastroenterology.
62:880–886. 2015.PubMed/NCBI
|
|
23
|
Marklein D, Graab U, Naumann I, Yan T,
Ridzewski R, Nitzki F, Rosenberger A, Dittmann K, Wienands J,
Wojnowski L, et al: PI3K inhibition enhances doxorubicin-induced
apoptosis in sarcoma cells. PLoS One. 7:e528982012. View Article : Google Scholar : PubMed/NCBI
|
